(Q27851892)

English

Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.

scientific article

In more languages

Statements

scholarly article

2 references

13 November 2016

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

0 references

Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

Sebastian Stintzing

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Dominik P Modest

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Thomas Brodowicz

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Andreas Jung

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Jens Neumann

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Ruediger P Laubender

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Janja Ocvirk

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Galina Kurteva

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Zsuzsanna Papai

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Regina Knittelfelder

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Thomas Kirchner

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Volker Heinemann

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Christoph C Zielinski

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

29 August 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

83

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

241-247

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

The Ras signal transduction pathway

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

Cetuximab for the treatment of colorectal cancer.

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

GTPase-activating proteins: helping hands to complement an active site.

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

Prevalence of ras gene mutations in human colorectal cancers

1 reference

https://api.crossref.org/works/10.1159%2F000339534

21 January 2018

Identifiers

10.1159/000339534

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22948721%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27851892&oldid=1631544151"